Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2016 | Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials | Menter M.A.; Papp K.A.; Cather J.; Leonardi C.; Pariser D.M.; Krueger J.G.; Wohlrab J.; Amaya-Guerra M.; Kaszuba A.; Nadashkevich O.; TSEN-FANG TSAI ; Gupta P.; Tan H.; Valdez H.; Mallbris L.; Tatulych S. | Journal of Drugs in Dermatology | 22 | 23 | |
2018 | Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study | Valenzuela F.; Korman N.J.; Bissonnette R.; Bakos N.; TSEN-FANG TSAI ; Harper M.K.; Ports W.C.; Tan H.; Tallman A.; Valdez H.; Gardner A.C. | British Journal of Dermatology | 47 | 43 |